"Clinical Use

Detect chronic kidney disease (CKD) in adults
Monitor CKD therapy and/or progression in adults

Clinical Background

About 37 million people in the United States are currently affected by CKD, and the prevalence of ensuing kidney failure is rising.1 Since evidence has shown that treatment at earlier stages is generally effective in preventing or delaying adverse outcomes, monitoring patients with and at risk for CKD becomes critically important for decreasing morbidity and mortality.

The Kidney Disease Improving Global Outcomes (KDIGO) guideline defines CKD by the presence of glomerular filtration rate (GFR) <60 mL/min/1.73m2 for >3 months and/or evidence of kidney damage (eg, structural abnormalities, histologic abnormalities, albuminuria, urinary sediment abnormalities, renal tubular disorders, and/or history of kidney transplantation) for >3 months.2 Thus, monitoring should include tests for GFR, albuminuria, and urine sediment.

GFR has traditionally been estimated based on 24-hour creatinine clearance; however, a calculation of estimated glomerular filtration rate (eGFR) is now recommended by the National Institutes of Health (NIH) and the National Kidney Foundation. eGFR based on serum creatinine and/or cystatin C is a simpler and generally more reliable test."

Includes
Albumin, Albumin/Globulin Ratio (calculated), Alkaline Phosphatase, ALT, AST, BUN/Creatinine Ratio (calculated), Calcium, Calcium (adjusted for albumin), Carbon Dioxide, Chloride, Creatinine with GFR Estimated, Globulin (calculated), Glucose, Potassium, Sodium, Total Bilirubin, Total Protein, Urea Nitrogen
Patient Preparation
Fasting specimen is preferred

Methodology
See individual tests

Reference Range(s)
See Laboratory Report